MS Patients' Real-World kesimpta use tracked in new study
NCT ID NCT05090033
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study followed 103 adults with relapsing multiple sclerosis who were taking Kesimpta (ofatumumab). Researchers used a mobile app to track how often patients took their medication on time and compared their reported symptoms with clinical results. The goal was to better understand real-world treatment patterns and how patients feel during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Concord, New South Wales, 2139, Australia
-
Novartis Investigative Site
Southport, Queensland, 4222, Australia
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Heidelberg, 3084, Australia
-
Novartis Investigative Site
St Leonards, 2065, Australia
Conditions
Explore the condition pages connected to this study.